Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


For Novartis, No Relax’in On Serelaxin: More Trials Likely

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis released mixed Phase III data on its heart failure candidate at the American Heart Association Scientific Sessions, showing the drug reduced symptoms of acute heart failure but failed to demonstrate an improvement on a second endpoint, cardiovascular death and hospital stays at 60 days.


Related Content

Stick To Basics: Attempt To Improve Heart Failure Symptomatic Endpoint Trips Up Novartis’ Serelaxin
FDA Advisors Think Novartis’ Serelaxin Could Perform Better On More Difficult Endpoints
Novartis Likely Stuck Waiting For Second Phase III For Serelaxin Approval
Novartis’ Serelaxin Is Early Victim Of East Coast Snow Storm
Novartis Poised To Be First To Market With IL-17 Blocker For Psoriasis
CHMP Rejects Serelaxin But Clears Albiglutide, Riociguat And Lurasidone
A Challenging Q3 For Novartis, But Diovan Generic Delay Offers A Reprieve


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts